Sean Ong
@seanong.bsky.social
ID doc and joint PhD candidate at University of Toronto + University of Melbourne. Talk to me about clinical trial design and methodology, bloodstream infections, S. aureus, and Gram negatives 🦠
🇸🇬🇨🇦🇦🇺
🇸🇬🇨🇦🇦🇺
That's right! Analysis completed and manuscript in preparation. Coming to a journal near you hopefully soon 🤞
September 14, 2026 at 6:06 PM
That's right! Analysis completed and manuscript in preparation. Coming to a journal near you hopefully soon 🤞
Reposted by Sean Ong
Hi Gabriele! Guess what- with @germhuntermd.bsky.social & quite a few others, we are gearing up to launch an #IDjournalclub on Bsky and it looks like this paper is the one we'll start with. 😊 We will get that going soooon!! (Also, Communicable will work on a follow-up POET2 ep!)
#IDSky #MedSky
#IDSky #MedSky
September 9, 2026 at 8:16 AM
Hi Gabriele! Guess what- with @germhuntermd.bsky.social & quite a few others, we are gearing up to launch an #IDjournalclub on Bsky and it looks like this paper is the one we'll start with. 😊 We will get that going soooon!! (Also, Communicable will work on a follow-up POET2 ep!)
#IDSky #MedSky
#IDSky #MedSky
Thank you! I completely agree, hence why reporting individual components separately is important. But I don't think we've seen this theoretical concern bear out in real trials in ID yet (granted, n is still very low so far for trials using DOOR as primary outcome).
April 17, 2026 at 3:15 PM
Thank you! I completely agree, hence why reporting individual components separately is important. But I don't think we've seen this theoretical concern bear out in real trials in ID yet (granted, n is still very low so far for trials using DOOR as primary outcome).
Our first published commentary on the DOTS trial explains the use of the DOOR outcome and discusses the benefits and drawbacks associated with using this outcome.
www.cmi-comms.org/article/S295...
www.cmi-comms.org/article/S295...
Breaking down the Desirability of Outcome Ranking (DOOR): unpacking the methodology behind the Dalbavancin as an Option for Treatment of Staphylococcus aureus Bacteremia (DOTS) trial
Desirability of Outcome Ranking (DOOR) outcomes such as the primary outcome of the
DOTS (Dalbavancin as an Option for Treatment of Staphylococcus aureus Bacteremia)
trial can improve statistical effic...
www.cmi-comms.org
November 30, 2025 at 11:40 PM
Our first published commentary on the DOTS trial explains the use of the DOOR outcome and discusses the benefits and drawbacks associated with using this outcome.
www.cmi-comms.org/article/S295...
www.cmi-comms.org/article/S295...
We will publish regular commentaries on new RCTs in ID/Micro, with a focus on methodologic aspects of these studies. A course focused on clinical trials design and methodology is in the works and will run Nov 2026; keep a look out for that. Read more here: doi.org/10.1016/j.cm...
The CLARITY initiative: Clinical Literature Appraisal and Research education in InfecTious diseases and microbiologY
Over the past two decades, the generation and application of clinical evidence in
the fields of clinical infectious diseases and microbiology have entered a new era:
one in which clinical guidelines a...
www.cmi-comms.org
November 30, 2025 at 11:40 PM
We will publish regular commentaries on new RCTs in ID/Micro, with a focus on methodologic aspects of these studies. A course focused on clinical trials design and methodology is in the works and will run Nov 2026; keep a look out for that. Read more here: doi.org/10.1016/j.cm...
This article is a companion piece to our previous review on hierarchical composite endpoints (HCEs) (doi.org/10.1093/cid/...), where we provided a conceptual overview of HCEs and explained the different analytic methods and possible target parameters associated with their use.
Making Sense of Hierarchical Composite End Points in Randomized Clinical Trials—A Primer for Infectious Diseases Clinicians and Researchers
Hierarchical composite end points (HCEs) are increasingly being used in infectious diseases research. In this review aimed at educating the clinical reader
doi.org
November 30, 2025 at 11:30 PM
This article is a companion piece to our previous review on hierarchical composite endpoints (HCEs) (doi.org/10.1093/cid/...), where we provided a conceptual overview of HCEs and explained the different analytic methods and possible target parameters associated with their use.